Fig. 2.

Effects of anti-EGF VacAbs in combination with ALK and RET inhibitors in ALK and RET translocated cell lines, respectively. TKI's were added at the final concentrations indicated, EGF or TGFα at 10 ng/mL, antibodies at 1/50 or 1/5 dilution in experiments with EGF and TGFα, respectively. Medium was RPMI+0.5% HS in all cases. (A-I) Results of 72 h proliferation assays. Data were pooled from at least three different experiments and presented as mean ± SEM.*, P < 0.05 compared to C-Ab treated cells. C-Ab, control antibodies; Ab, anti-EGF VacAbs.